Ferritin: a biomarker of cardiovascular diseases in diabetic patients

Main Article Content

Amanda Justi
Pamela Tatsch
Luciano Oliveira Siqueira

Abstract

Introduction: Diabetes Mellitus (DM) is a clinical condition characterized by hyperglycemia default in secretion and/or insulin resistance. Objective: Check the correlation between markers of inflammation, high sensitivity C-reactive protein (hs-CRP), ferritin and lipids in diabetic patients. Methods: We carried out the analysis of lipid profiles of 50 type 2 diabetic patients, with an average of four years of diagnosis. We analyzed the plasma concentration of glucose, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, triglycerides, ferritin and hs-CRP. Results: The study showed a strong positive correlation between ferritin and hs-CRP (r=0.85), between ferritin and LDL cholesterol and triglycerides (r=0.91, r=0.91), moderate positive correlation to total cholesterol (r=0.63); moderate negative for HDL cholesterol (r=0.38). Conclusion: The results indicate that ferritin shows a strong positive correlation with hs-CRP, triglycerides and LDL cholesterol that, when considered in combination, suggest the suspicion of active inflammatory process and a greater chance of atherosclerosis in these patients.

Downloads

Download data is not yet available.

Article Details

How to Cite
Justi, A., Tatsch, P., & Siqueira, L. O. (2019). Ferritin: a biomarker of cardiovascular diseases in diabetic patients. ABCS Health Sciences, 44(1). https://doi.org/10.7322/abcshs.v44i1.1145
Section
Original Articles
Author Biographies

Amanda Justi, Curso de Medicina, Faculdade de Medicina, Universidade de Passo Fundo (UPF) – Passo Fundo (RS)

Acadêmica de Medicina

Pamela Tatsch, Curso de Farmácia, Instituto de Ciências Biológicas, Universidade de Passo Fundo (UPF) – Passo Fundo (RS)

Farmaceutica 

 

Luciano Oliveira Siqueira, Curso de Farmácia, Instituto de Ciências Biológicas, Universidade de Passo Fundo (UPF) – Passo Fundo (RS)

Farmaceutico (UFSM)

Especialista em análises clínicas e toxicológicas (UFSM)
Mestre em Bioquímica (UFSM)

Doutor em BIoquímica (UFRGS)

MBA em gestão estratégica e inovação em negócios (UPF)

References

1. Fernandes MPA, Pace AE, Zanetti ML, Foss MC, Donadi EA. Fatores imunogenéticos associados ao diabetes mellitus do tipo 1. Rev Latino-Am Enfermagem. 2005;13(5):743-9. http://dx.doi.org/10.1590/S0104-11692005000500020

2. Sociedade Brasileira de Diabetes (SBD). Diretrizes da Sociedade Brasileira de Diabetes: 2017-2018. São Paulo: Clannad, 2017.

3. Schmidt IM, Duncan BB, Silva GA, Menezes AM, Monteiro CA, Barreto SM, et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet. 2011;377(9781):1949-61. http://dx.doi.org/10.1016/S0140-6736(11)60135-9

4. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;102(1):42-47. https://dx.doi.org/10.1161/01.cir.102.1.42

5. Moehlecke M, Leitão CB, Kramer CK, Rodrigues TC, Nickel C, Silveiro SP, et al. Effect of metabolic syndrome and of its individual components on renal function of patients with type 2 diabetes mellitus. Braz J Med Biol Res. 2010;43(7):687-93.

6. Volp ACP, Alfenas RCG, Costa NMB, Minim VPR, Stringueta PC, Bressan J. Capacidade dos biomarcadores inflamatórios em predizer a síndrome metabólica. Arq Bras Endocrinol Metab. 2008;52(3):537-49. http://dx.doi.org/10.1590/S0004-27302008000300015

7. Lontchi-Yimagou E, Sobngwi E, Matsha TE, Kengne AP. Diabetes Mellitus and Inflammation. Curr Diab Rep. 2013;13(3)435-44. http://dx.doi.org/10.1007/s11892-013-0375-y

8. Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38(3):183-91. http://dx.doi.org/10.1016/j.diabet.2011.11.006

9. van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity- associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013;71(4);174-87.

10. Pithan E, Martins OMO. Marcadores inflamatórios e de disfunção endotelial: qual o papel na predição de risco. Rev Soc Cardiol RS. 2010; 18(20):1-11.

11. González AS, Guerrero DB, Soto MB, Díaz SP, del Olmo MM, Vidal O. Síndrome metabólico e inflamación. Clin Invest Arterioscl. 2006;18(3):89-95. http://dx.doi.org/10.1016/S0214-9168(06)73667-1

12. Cook NR, Paynter NP, Eaton CB, Manson JE, Martin LW, Robinson JG, et al. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation. 2012;125(14):1748-56. http://dx.doi.org/10.1161/CIRCULATIONAHA.111.075929

13. Rosa Neto NS, Carvalho JF. O uso de provas de atividade inflamatória em reumatologia. Rev Bras Reumatol. 2009;49(4):413-30. http://dx.doi.org/10.1590/S0482-50042009000400008

14. Kell DB, Pretorius E. Serum ferritin is as important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6(4):748-73. http://dx.doi.org/10.1039/c3mt00347g

15. Gomes AC, Moreira AC, Mesquita G, Gomes MS. Modulation of Iron Metabolism in Response to Infection: Twists for All Tastes. Pharmaceuticals. 2018;11(3):E84. http://dx.doi.org/10.3390/ph11030084

16. González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr. 2006;60(6):802-9. http://dx.doi.org/10.1038/sj.ejcn.1602384

17. Almeida CA, Pinto AP, Ricco RG, Pepato MT, Brunetti IL. Determination of glycemia and insulinemia and the Homeostasis model assessment (HOMA) in schoolchildren and adolescents with normal body mass index. J Pediatr. 2008; 84(2):136-40. http://dx.doi.org/10.2223/JPED.1767

18. You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics. 2003;13(1):25-30. http://dx.doi.org/10.1152/physiolgenomics.00124.2002

19. Ryan BJ, Van Pelt DW, Guth LM, Ludzki AC, Gioscia-Ryan RA, Ahn C, et al. Plasma ferritin concentration is positively associated with in vivo fatty acid mobilization and insulin resistance in obese women. Exp Physiol. 2018. http://dx.doi.org/10.1113/EP087283

20. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803-11.

21. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F, et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation. 1997;96(10):3300-7. https://dx.doi.org/10.1161/01.CIR.96.10.3300

22. Haidari M, Javadi E, Sanati A, Hajilooi M, Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem. 2001;47(9):1666-72.